Blog - Page 3591 of 5669

TuesdayDec 21, 2010 1:24 pm

Ivanhoe Energy Inc. (IVAN) Reports Major Natural Gas Discovery in China, 13 Million Cubic Feet per Day Initial Flow Rate

Ivanhoe Energy, www.ivanhoeenergy.com – has made a name for itself on the global stage as an independent heavy-oil development/production innovator, proudly announcing a major natural gas discovery in China today, with initial flow rates of 13M cubic feet per day. Jointly making the announcement were President and COO of Ivanhoe, David Dyck, Co-Chairman of Sunwing Energy Ltd. (Ivanhoe’s China-focused subsidiary), Robert Friedland and President of Sunwing, Gerry Moench. Dyck praised initial flow rates at the Yixin-2 well, which is situated within Sunwing’s approximately 660k-acre Zitong Block, in one of China’s oldest and most prolific gas regions, the Sichuan Province. The…

TuesdayDec 21, 2010 11:45 am

China Nepstar Chain Drugstore Ltd. (NPD) Video Chart for Tuesday, December 21, 2010

NPD established a very strong resistance level earlier this year around $3.20 before breaking through it to make new highs. The stock price has settled back down on this area again and is on radar to hold the support and trend upward. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts.php Let us hear your thoughts below:

TuesdayDec 21, 2010 11:28 am

Emisphere Technologies (EMIS.OB) Extends Exclusive Agreement with Novo Nordisk (NVO) for Diabetes Treatment

Emisphere Technologies Inc. and Novo Nordisk A/S today announced their extended partnership to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® technology. The exclusive development and license agreement is in line with Novo Nordisk’s overall dedication to diabetes research. "This is an encouraging agreement on a promising technology for oral administration of proteins. We are delighted to continue working with Emisphere and their Eligen® Technology. It fits very well with Novo Nordisk's strategy within diabetes research," Peter Kurtzhals, senior vice president of Diabetes Research Unit at Novo Nordisk stated…

TuesdayDec 21, 2010 10:41 am

Genmed Holding Corp. (GENM.OB) to Enter the European Generic Pharma Market

Genmed Holding Corp. is focused on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. The company began its generic business in 2008 and currently operates through its 100%-owned Dutch subsidiary, Genmed B.V. The company announced today its entry into the European generic drug market with the receipt of its first marketing and distribution license for paracetamol. Also known as acetaminophen, paracetamol is an over-the-counter drug used to treat mild to moderate pain from headaches, backaches, osteoarthritis and to reduce fever. Genmed first filed its application paperwork for paracetamol 500 milligram tablets with the…

TuesdayDec 21, 2010 10:27 am

Discover Your Next Profitable Investment with Trader Power

TraderPower was established to empower investors with all the resources they need to make profitable trading decisions. Using the vast resources on the TraderPower website, the investment community can discover undervalued small-cap companies, learn how to properly analyze investment opportunities, and utilize free research tools for in-depth evaluation. TraderPower’s #1 focus is on connecting investors with undervalued small-cap companies that are trading far below their true worth. With an estimated 15,000 publicly traded companies, it’s no surprise that these stocks exist. Of course once these neglected equities begin to get noticed, the climb to their fair valuation can be exceptionally…

TuesdayDec 21, 2010 9:46 am

Sunesis Pharmaceuticals, Inc. (SNSS) Launches Phase 3 VALOR Trial for Vosaroxin Drug

Today, Sunesis Pharmaceuticals, Inc. released updates on its pivotal Phase 3 VALOR trial of vosaroxin, the company’s lead drug candidate in the study of acute myeloid leukemia (AML). Sunesis announced that the first patient has been randomized and dosed with blinded study treatment. The VALOR trial is a multinational, randomized, double-blind, placebo-controlled, pivotal trial which is expected to enroll 450 evaluable patients at leading sites in the U.S., Canada, Europe, Australia and New Zealand. Patients in the VALOR trial will be randomized in blinded manner to receive either vosaroxin or placebo on days one and four of each treatment cycle.…

TuesdayDec 21, 2010 9:43 am

Ivanhoe Energy Inc. (IVAN) Reports Successful Natural Gas Well in China

Ivanhoe Energy Inc. reported the successful completion of a natural gas well at the company’s properties in China. Ivanhoe Energy Inc. said that the Yixin-2 well produced natural gas at a peak rate of 13 million cubic feet per day, with average production between 9 and 10 million cubic feet per day during a 24 hour test period. The well targeted the Xu-4 formation and has been shut in to allow pressure build up. Ivanhoe Energy Inc. reported that the Yixin-2 well was drilled and completed on the Zitgong block located in Sichuan, China. The Zitgong block is approximately 660,000…

TuesdayDec 21, 2010 9:13 am

American Surgical Holdings, Inc. (ASRG.OB) Enters Into Definitive Merger Agreement

American Surgical Holdings, Inc. announced yesterday that they entered into a definitive merger agreement. With the agreement, American Surgical will be acquired and taken private by AH Holdings Inc., an affiliate of Great Point Partners, I LP (GPP), a Greenwich, Connecticut-based private equity fund. At the closing of the transaction, American Surgical's stockholders will receive $2.87 per share in cash, which represents a 205 percent premium to the average daily trading price of $0.941 over the 90 days prior to the execution and public announcement of the transaction. The closing price of the Company's common stock on the last trading…

TuesdayDec 21, 2010 9:10 am

Omnicity Corp. (OMCY.OB) Releases First Quarter Financial Results

The Midwest's largest and fastest growing fixed Wireless Internet Service Provider, Omincity Corp., has released its first quarter financial results through October 2010. Revenues for the 1st quarter of 2010 increased 105%, rising from $617,000 in 2009 to $1.26 million this quarter. Cash flow improvements were even more dramatic, with Omnicity posting its first ever EBITDA positive quarter of $40,000 compared to negative $395,000 for the first quarter of last year and negative $17,000 for the fourth quarter of 2010. The results come as the latest in a series of five continually improving cash flow quarters. The success is attributed…

TuesdayDec 21, 2010 8:48 am

Simulated Environment Concepts, Inc. (SMEV.PK) SpaCapsule to be Featured in Hammacher-Schlemmer and FrontGate Publications

Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic and wellness equipment, today announced that its flagship SpaCapsule has been included in the prestigious Hammacher-Schlemmer and FrontGate publications as increased interest continues to emerge during the holiday season. “We are very excited to have SpaCapsule included in such prestigious publications at a time when the holiday season is approaching and personal interest in the machine is on a rise,” stated Dr. Ilya Spivak, Marketing Director of Simulated Environment Concepts (SE Concepts) and Co-Inventor of the SpaCapsule. “We have seen a steady increase in orders over the past several weeks…

Site Search

Company Search